A six months of exenatide treatment led to improvements in fibrosis score, reduction in body weight, and regulation of blood glucose in nonalcoholic fatty liver disease (NAFLD) people suffering from type 2 diabetes, according to the findings of a retrospective study published in Scientific Reports.

Researchers undertook this study for assessing the link between exenatide therapy and fibrosis scores. The impact of exenatide therapy on fibrosis scores was assessed in type 2 diabetes mellitus people (n=50) with NAFLD (also known as metabolic associated fatty liver disease [MAFLD]).

Before and after six months of therapy, the aspartate aminotransferase to platelet ratio index (APRI) scores, NAFLD score (NFS), and fibrosis-4 (FIB4) were estimated. Following six months of exenatide therapy, a considerable drop in the APRI and NFS scores were noted. However, no considerable alteration in the FIB-4 score was noted. Thus, exenatide treatment is beneficial for NAFLD people diagnosed with diabetes.